Miruvor
Sign up
The short answer

What studies of Ondansetron (Zofran) found

3papers on Ondansetron (Zofran)
33people in 1 study testing Ondansetron (Zofran) alone
1randomised trial, the strongest kind of study

At a glance, by condition

ME/CFS: D Little or no difference

Based on the strongest evidence, the placebo trial (very low certainty): 2 findings, all D.

2 outcomes rated · see each below

How we got this

Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.

What this means: Studies found little or no difference with Ondansetron (Zofran) for ME/CFS. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.

Ask about this treatment

Sign up free to read the rest of what studies found.

You’ll see the full picture: how each symptom fared, every grade with its reasons, side effects, the doses studied and all 3 papers.

The grades, in plain words

Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.

  1. A
    HelpsImprovement, high certainty
    Probably helpsImprovement, moderate certainty
  2. B
    May helpImprovement, low certainty
  3. C
    Might help, very uncertainImprovement, very low certainty
    Mixed resultsStudies disagree
  4. Ondansetron (Zofran) · ME/CFS is hereD
    Little or no differenceStudies found little or no difference
  5. F
    HarmsIt made things worse

By symptom and daily life

ME/CFS

Symptoms

Fatigue1 study · 33 people took Ondansetron (Zofran) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 67 people found no clear difference; a small benefit can't be ruled out.

The placebo trial67 randomised · 10 weeks · 16 mg per day, at night

No clear difference in fatigue.

The evidence is very uncertain about the effect of ondansetron (Zofran) on fatigue in ME/CFS. Little or no difference · very low certainty D

  • High risk of bias (RoB 2) in the results that carry most of the weight
  • One trial of 67 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. (2010)

    People in the study
    67 randomised
    Dose
    16 mg per day, at night
    Outcome
    CIS-fatigue Checklist Individual Strength fatigue severity subscale
    Effect
    no clear difference
    Risk of bias
    RoB 2: High
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    High

Daily life and health overall

Daily functioning1 study · 33 people took Ondansetron (Zofran) Little or no difference D
Very low certainty

Why this grade: Little or no difference, very low certainty, from randomised trials: some concerns about bias (RoB 2); one trial of 67 people found no clear difference; a small benefit can't be ruled out.

The placebo trial67 randomised · 10 weeks · 16 mg per day, at night

No clear difference in daily functioning.

The evidence is very uncertain about the effect of ondansetron (Zofran) on daily functioning in ME/CFS. Little or no difference · very low certainty D

  • Some concerns about bias (RoB 2)
  • One trial of 67 people found no clear difference; a small benefit can't be ruled out
See the 1 study
  1. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial. (2010)

    People in the study
    67 randomised
    Dose
    16 mg per day, at night
    Outcome
    SIP-8 Sickness Impact Profile-8
    Effect
    no clear difference
    Risk of bias
    RoB 2: Some concerns
    Randomisation process
    Low
    Deviations from intended interventions
    Low
    Missing outcome data
    Low
    Measurement of the outcome
    Low
    Selection of the reported result
    Some concerns

Side effects

Stopping because of side effects2 studies
Side effects studies reported2 kinds
Side effects studies reported, and how many studies reported each
Side effectStudies that reported it
Nausea or stomach upset2 studies
Trouble sleeping1 study

Doses studied

What researchers used, as the papers print it; not a recommendation.

  1. 1Start

    8 to 16 mg at the start

  2. 2Top dose

    Most often 8 mg (1 of 2 studies)

Doses across 2 studies

8 to 16 mg.

Each study’s dose, as printed

All papers

  1. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.2010 · placebo trial · 67 randomised
    Summary

    The study was a randomized, placebo-controlled, double-blind clinical trial at Radboud University Nijmegen Medical Centre, The Netherlands. Sixty-seven adult patients who fulfilled the US Centers for Disease Control and Prevention criteria for chronic fatigue syndrome participated. Thirty-three patients were allocated to ondansetron and 34 to placebo. During 10 weeks, patients took either ondansetron 16 mg per day (two 8-mg tablets) or 2 placebo tablets at night. The primary outcome variables were fatigue severity on the Checklist Individual Strength fatigue severity subscale (CIS-fatigue) and functional impairment on the Sickness Impact Profile-8 (SIP-8). Secondary measures included physical activity measured with an actometer and daily observed fatigue (DOF). Analysis of covariance showed no significant differences between the ondansetron- and placebo-treated groups during the 10-week treatment period in fatigue severity and functional impairment. Posttreatment actometer activity scores and DOF scores of the ondansetron and placebo group did not differ significantly. In the placebo arm, no participants dropped out. Three patients in the ondansetron arm dropped out within the first 2 weeks; 2 patients in the ondansetron group had missing values for posttreatment measurements. The main reason for discontinuing was an increased general feeling of malaise. Four patients (3 ondansetron and 1 placebo) had complaints of constipation, and a laxative syrup was prescribed. No other important side effects were reported in either group. In both treatment groups, an equal number of 8 patients showed an improvement of more than 10 points in the CIS-fatigue severity. Authors noted they did not monitor patient compliance on a daily basis and did not assess baseline serotonin status.

  2. Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.2000 · compared with another group · 20 in the study · 19 with outcome data
    Summary

    This open-labelled study asked whether 5-HT3 receptor antagonists help chronic fatigue syndrome (CFS). It included 20 patients meeting CDC criteria; 10 received oral tropisetron 5 mg once daily and 10 received oral ondansetron 8 mg twice daily for 15 days. Fatigue and capability were measured with visual analog scales (VAS). 19 patients finished; 1 patient in the tropisetron group dropped out on day 3 due to headaches, dizziness and daze, possibly related to study drug. In the tropisetron group, 6/9 patients documented benefit on VAS fatigue and 7/9 on VAS capability; mean changes were z20.3% and z29.9%. In the ondansetron group, 8/10 documented benefit on VAS fatigue and 8/10 on VAS capability; mean changes were z27.9% and z23.7%. Score changes in responders were more pronounced in the tropisetron group. The frequency of concomitant symptoms did not differ significantly between treatment groups. Sleep disturbances increased in 1 (ondansetron) and 2 (tropisetron) patients; constipation in 2 and 3 patients. No unexpected adverse events were reported. Overall analysis of both studies showed improvement §35% in approximately one third of patients in both VAS; another third reported moderate improvement §10% to 35%; 5% rsp. 11% felt deterioration. The authors state limitations: small sample size, not double-blind, not placebo-controlled.

A little hope, every Sunday

New recovery stories and data-driven research on ME/CFS and long COVID. Ideas worth considering, and the evidence behind them.

Free · Unsubscribe anytime